Fierce Biotech March 28, 2024
Exact Sciences has put forward positive data on its approach to screening for esophageal tumors and the disease’s precancerous conditions with a method that may allow patients to skip a sedated endoscopic exam.
The company’s Oncoguard Esophagus test—being developed through a collaboration with the Mayo Clinic—begins with a swallowable capsule attached to, essentially, a string. Once it reaches the stomach, acid dissolves its coating to reveal an expanding sponge. After less than 10 minutes, it’s drawn back up the esophagus, collecting cell samples on the way out.
After that, Exact Sciences’ test searches for specific DNA biomarkers tied to esophageal adenocarcinoma and its precursor condition known as Barrett’s esophagus, which involves changes to the organ’s natural lining in the face...
Today's Sponsors
Today's Sponsor